title: [Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer  with Brain Metastasis].
abstract: Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, significantly affects the patients' quality of life. The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without treatment. The targeted therapy based on lung cancer driven gene is a new treatment. Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach. The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work.
authors: Oncology Department, General Hospital of PLA, Beijing 100853, China.
authors: Qi
authors: Q
authors: Song
authors: Oncology Department, General Hospital of PLA, Beijing 100853, China.
authors: Shunchang
authors: S
authors: Jiao
authors: Oncology Department, General Hospital of PLA, Beijing 100853, China.
authors: Fang
authors: F
authors: Li
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000473:pathology*; D058990:Molecular Targeted Therapy; D016896:Treatment Outcome